US Pharma MarketingCVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The top pharmacy benefit manager in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, allowing a significant number of patients to gain access to the drugs through their existing insurance.
Source: FiercePharma